Javascript must be enabled to continue!
Influenza D pseudotyped lentiviruses: production, neutralisation assay and serological surveillance
View through CrossRef
Influenza D virus (IDV) has been reported in many animal species and potentially humans worldwide. Cattle are considered the major reservoir. There are currently three main lineages based on the haemagglutinin-esterase (HEF) gene: D/OK, D/660 and D/Japan. We performed pilot surveillance for IDV by using pseudotyped lentivirus (PVs) to generate a cell-based test to identify prior-exposure to IDV in animals. The expression plasmids of the HEF genes, D/swine/Italy/2015, D/bovine/France/2014, and D/bovine/Ibaraki/2016, were constructed. The HEF plasmid was co-transfected with lentiviral vector plasmid expressing luciferase, lentiviral Gag-Pol plasmid, and HAT protease plasmid in producer cells (HEK293T/17). Three days post-transfection, supernatants were collected and used for titration on various cell lines and in micro-neutralisation tests. Sera from pigs vaccinated with D/swine/Italy/2015 and D/swine/Oklahoma/2011 were used to undertake a preliminary validation of the micro-neutralisation assay. All pig sera have neutralising activity to influenza D (Italy) pseudotyped lentiviruses. Cow and sheep sera, 145 and 114 specimens, respectively, collected from UK farms were screened using the micro-neutralisation test. We found 97 bovine sera (66.9%) were influenza D antibody positive. Collectively, pseudotyped lentivirus technology opens up opportunities for serological surveillance of influenza D viruses.
Microbiology Society
Title: Influenza D pseudotyped lentiviruses: production, neutralisation assay and serological surveillance
Description:
Influenza D virus (IDV) has been reported in many animal species and potentially humans worldwide.
Cattle are considered the major reservoir.
There are currently three main lineages based on the haemagglutinin-esterase (HEF) gene: D/OK, D/660 and D/Japan.
We performed pilot surveillance for IDV by using pseudotyped lentivirus (PVs) to generate a cell-based test to identify prior-exposure to IDV in animals.
The expression plasmids of the HEF genes, D/swine/Italy/2015, D/bovine/France/2014, and D/bovine/Ibaraki/2016, were constructed.
The HEF plasmid was co-transfected with lentiviral vector plasmid expressing luciferase, lentiviral Gag-Pol plasmid, and HAT protease plasmid in producer cells (HEK293T/17).
Three days post-transfection, supernatants were collected and used for titration on various cell lines and in micro-neutralisation tests.
Sera from pigs vaccinated with D/swine/Italy/2015 and D/swine/Oklahoma/2011 were used to undertake a preliminary validation of the micro-neutralisation assay.
All pig sera have neutralising activity to influenza D (Italy) pseudotyped lentiviruses.
Cow and sheep sera, 145 and 114 specimens, respectively, collected from UK farms were screened using the micro-neutralisation test.
We found 97 bovine sera (66.
9%) were influenza D antibody positive.
Collectively, pseudotyped lentivirus technology opens up opportunities for serological surveillance of influenza D viruses.
Related Results
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic
Please cite this paper as: Borders‐Hemphill and Mosholder (2012) U.S. utilization patterns of influenza antiviral medications during the 2009 H1N1 influenza pandemic. Influenza and...
Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
Abstract
Objectives To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-...
Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay
Abstract
Objectives To assess whether a commercially available CE-IVD, ELISA-based surrogate neutralisation assay (cPass, Genscript) provides a genuine measure of SARS-CoV-...
Burden and seasonality of medically attended influenza like illness (ILI) in Ethiopia, 2012 to 2017
Burden and seasonality of medically attended influenza like illness (ILI) in Ethiopia, 2012 to 2017
Abstract
Background
The influenza virus spreads rapidly around the world in seasonal epidemics, resulting in significant morbidity and mortality. In...
A severe 2017 influenza season dominated by influenza A(H3N2), Victoria, Australia
A severe 2017 influenza season dominated by influenza A(H3N2), Victoria, Australia
Surveillance for influenza-like illness (ILI) and laboratory-confirmed influenza in Victoria, Australia is undertaken jointly by the Victorian Infectious Diseases Reference Laborat...
Environmental Surveillance Protocols for Highly Pathogenic Avian Influenza (HPAI) v2
Environmental Surveillance Protocols for Highly Pathogenic Avian Influenza (HPAI) v2
EnvironmentalSurveillance Protocols for Highly Pathogenic Avian Influenza (HPAI) This comprehensive protocol suite enables systematic environmental surveillance for avian influenza...
Burden of influenza in Latin America and the Caribbean: a systematic review and meta‐analysis
Burden of influenza in Latin America and the Caribbean: a systematic review and meta‐analysis
Please cite this paper as: Savy et al. (2012) Burden of influenza in Latin America and the Caribbean: a systematic review and meta‐analysis. Influenza and Other Respiratory Viruses...
The Clinical Effectiveness and Tolerability of Oseltamivir in Unvaccinated against Influenza Pediatric Patients in Two In-fluenza seasons after the COVID-19 pandemic.The Impact of Comorbidities on Hospitalization for Influenza in Children.
The Clinical Effectiveness and Tolerability of Oseltamivir in Unvaccinated against Influenza Pediatric Patients in Two In-fluenza seasons after the COVID-19 pandemic.The Impact of Comorbidities on Hospitalization for Influenza in Children.
Antiviral therapy such as Oseltamivir has been recommended for hospitalized children with suspected and confirmed influenza for almost 20 years. The therapy is officially authorize...

